Free Trial
NASDAQ:HLVX

HilleVax Q2 2025 Earnings Report

HilleVax logo
$2.08 +0.01 (+0.48%)
Closing price 04:00 PM Eastern
Extended Trading
$2.08 +0.00 (+0.19%)
As of 06:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HilleVax EPS Results

Actual EPS
-$0.11
Consensus EPS
-$0.14
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

HilleVax Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

HilleVax Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

HilleVax's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 15, 2025 at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

HilleVax Earnings Headlines

HilleVax Announces Merger Agreement with XOMA
HilleVax (HLVX) Expected to Announce Earnings on Thursday
Musk’s Project Colossus could mint millionaires
I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history. And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI.
HilleVax Reports Second Quarter 2025 Financial Results
See More HilleVax Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email.

About HilleVax

HilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

View HilleVax Profile

More Earnings Resources from MarketBeat